Seelos Therapeutics (Nasdaq: SEEL), a company working on therapies for amyotrophic lateral sclerosis (ALS) and other central nervous system disorders (CNS) has been struck by a trial failure.
Shares in the company were trading around 5% lower on Thursday, after the rare disease specialist released top-line data from the Phase II/III HEALEY ALS study.
The trial, which was designed to evaluate SLS-005 as a treatment for ALS, did not meet statistical significance for either the primary or secondary efficacy endpoints.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze